:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Nicolas Richard, Mathurin Fumery
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70149
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
by: C. Ramos‐Belinchon, et al.
Published: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
by: Nicolas Richard, et al.
Published: (2026)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
by: Vincenzo Stranges, et al.
Published: (2025)

Editorial: Upadacitinib in Perianal Crohn's Disease
by: Manjeet Kumar Goyal, et al.
Published: (2026)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
by: Shlomi Cohen, et al.
Published: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Jeffrey D McCurdy, et al.
Published: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
by: Shinichiro Shinzaki, et al.
Published: (2025)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Runqi Wang, et al.
Published: (2026)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
by: Rahul S. Dalal, et al.
Published: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
by: Jeffrey D McCurdy, et al.
Published: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
by: Péter Bacsur, et al.
Published: (2024)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
by: Stefano Siboni, et al.
Published: (2026)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
by: Lichao Qiao, et al.
Published: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
by: María Chaparro, et al.
Published: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
by: Nathan Grellier, et al.
Published: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
by: Jeffrey D. McCurdy, et al.
Published: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
by: Eric Lawitz, et al.
Published: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
by: Aakash Desai, et al.
Published: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
by: Olga P. Nyssen, et al.
Published: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
by: Rohit Mehtani, et al.
Published: (2026)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
by: Chia‐Chih Kuo, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
by: Jessica A. Fitzpatrick, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study
by: Clara Yzet, et al.
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
by: Ramin Ebrahimi, et al.
Published: (2025)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
by: Samantha Baillie, et al.
Published: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply
by: Stiliano Maimaris, et al.
Published: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
by: Máté Szilcz, et al.
Published: (2025)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
by: Jeongkuk Seo, et al.
Published: (2024)